Assesment of the Metabolomic Signature in COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
Metabolomics is the analysis of small molecules in a biological sample (cells, tissues or biological fluids). It can potentially detect very sensitively any change related to a pathology or exposure to a toxic agent. The analyses are fast, inexpensive and therefore applicable in routine, particularly in health care. Given the emergence of this new disease, COVID-19, there is a real need to better understand the pathophysiological mechanisms of SARS-CoV-2 infection. In this context, metabolomics could have a place and could lead to the development of interesting diagnostic or prognostic tools. The objective of this study is to identify, through the analysis of biological samples (blood and urine), whether there is a metabolomic signature in patients with COVID-19.

Official Title
-----------------
Assesment of the Metabolomic Signature in COVID-19 Patients (SignCov Study)

Conditions
-----------------
COVID 19

Intervention / Treatment
-----------------
* Other: COVID-19 patients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient over 18 years of age affiliated to a social security scheme consultant in the emergency department and/or being hospitalized for suspected SARS CoV infection confirmation, after medical examination, of the need for a biological examination (this will negate the need for additional venipuncture) Exclusion criteria: Patient who do not meet inclusion criteria Person subject to a guardianship order Opposition to the use of the data or samples (withdrawal of non-opposition) / Sponsor's or investigator's decision

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Interventional Model Description: Patient with COVID-19 disease
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: The metabolomic signature of COVID-19 patients<br>It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample. | Other: COVID-19 patients<br>* It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identifying the metabolomic signature | To dentified a metabolomic profile using liquid chromatography combined with mass spectrometry (LC-MS) on the serum and urine of COVID-19 patients | Enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of the metabolomic profile according to clinical severity. | Identification of the metabolomic profile of patients infected with SARS CoV 2 in the following subgroups: pauci-symptomatic patients, symptomatic patients without clinical severity criteria, and critically ill COVID-19 patients. | Enrollment |